Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Cystic Fibrosis
Interventions
BIOLOGICAL

KB001-A

DRUG

Placebo Comparator

Trial Locations (67)

2305

New Lambton

3052

Parkville

3420

Hamilton

6009

Nedlands

9016

Dunedin

10032

New York

10532

Hawthorne

10655

Worchester

11040

New Hyde Park

12208

Albany

15224

Pittsburgh

17033

Hershey

19102

Philadelphia

19104

Philadelphia

23219

Richmond

29425

Charleston

30322

Atlanta

31096

Haifa

32610

Gainesville

32806

Orlando

33136

Miami

33606

Tampa

36608

Mobile

37232

Nashville

37916

Knoxville

38105

Memphis

40202

Louisville

40536

Lexington

43205

Columbus

43606

Toledo

44106

Cleveland

45229

Cincinnati

45267

Cincinnati

45404

Dayton

46202

Indianapolis

48201

Detriot

49202

Petah Tikva

49503

Grand Rapids

52242

Iowa City

52621

Tel Litwinsky

53226

Milwaukee

53792

Madison

55455

Minneapolis

60025

Glenview

63104

St Louis

63110

St Louis

64108

Kansas City

72205

Little Rock

73104

Oklahoma City

75390

Dallas

78212

San Antonio

78723

Austin

80045

Aurora

83712

Boise

85016

Phoenix

85724

Tucson

87131

Albuquerque

90806

Long Beach

91240

Jerusalem

92868

Orange

94304

Stanford

94611

Oakland

04102

Portland

02115

Boston

03756

Hanover

Manchester

05446

Colchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Humanigen, Inc.

INDUSTRY